Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595423 | 0.81 | MEN1 (0.39) | EPHX2SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL10001421 | 0.81 | MEN1 (0.39) | EPHX2SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL17838782 | 0.78 | KMT2A (0.41) | EPHX2KMT2A | |
| SCHEMBL17838781 | 0.78 | KMT2A (0.41) | EPHX2KMT2A | |
| SCHEMBL14088977 | 0.74 | EPHX2 (0.48) | EPHX2KDM4EHTT | |
| SCHEMBL19091348 | 0.70 | DGAT1 (0.38) | KMT2A | |
| SCHEMBL16408932 | 0.70 | THRB (0.34) | — | |
| SCHEMBL25013987 | 0.68 | GNAI3 (0.41) | EPHX2 | |
| Quinic Acid SCHEMBL1286207 | 0.64 | HSD17B10 (0.39) | KDM4E | |
| Quinic Acid SCHEMBL14960616 | 0.64 | HSD17B10 (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3569230-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | Akeso Biomedical, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3068384-B1 | IRON COMPLEXES FOR THE REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | AKESO BIOMEDICAL INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9655912-B2 | Reduction of gastrointestinal tract colonisation by campylobacter | Akeso Biomedical, Inc. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150025026-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | MAHDAVI, JAFAR (GB) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025026-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | FABP2, MLN, MLNR | EPHX2 2663/4885SMN1; SMN2 3829/4885KMT2A 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.